Compare Diageo plc (DEO) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs DexCom, Inc. — how do they compare? Diageo plc trades at $86.73 (market cap $47.67B), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays a 2.3% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and DexCom, Inc. for 62 Days on average.
| DEO | DXCM | |
|---|---|---|
Market Cap | $47.67B | $31.86B |
Volume | 893,372 | 3,607,070 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $92.34 |
52-Week Low | $72.47 | $54.84 |
Typical Hold Time | 66 Days | 62 Days |
Enterprise Value | $68.09B | $31.32B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.98, up 2.66% with bullish technical indicators and strong institutional support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, while analyst consensus remains positive with 49% buy ratings.
The outlook remains favorable with restructuring savings and brand investments driving potential upside, though investors face risks from US market challenges and regulatory pressures. The stock's current valuation at 27.9x P/E appears reasonable given the company's market leadership and turnaround progress under new management.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
